NCT06631092 2026-02-20
Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer
NEC Bio B.V
Phase 1/2 Recruiting
Clinical Trials
7 trialsNCT05799144 2025-10-22
pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer
Vanderbilt-Ingram Cancer Center
Phase 2 Recruiting
NCT02529930 2022-07-13
An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3)
Nykode Therapeutics ASA
Phase 1/2 Completed
NCT04049864 2022-03-02
DNA Vaccination Against Neuroblastoma
Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
Phase EARLY_PHASE1 Unknown
NCT01706458 2021-06-18
Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer
University of Wisconsin, Madison
Phase 2 Completed
NCT01493154 2018-11-23
Safety Study of HPV DNA Vaccine to Treat Head and Neck Cancer Patients
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Terminated
NCT00988559 2018-07-09
Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed